Literature DB >> 12086748

The placebo effect in Parkinson's disease.

Raúl de la Fuente-Fernández1, A Jon Stoessl.   

Abstract

The biochemical bases of the placebo effect are still incompletely known. We show here that the placebo effect in Parkinson's disease is due, at least in part, to the release of dopamine in the striatum. We propose that the placebo effect might be related to reward mechanisms. The expectation of reward (i.e. clinical benefit) seems to be particularly relevant. According to this theory, brain dopamine release could be a common biochemical substrate for the placebo effect encountered in other medical conditions, such as pain and depression. Other neurotransmitters or neuropeptides, however, are also likely to be involved in mediating the placebo effect (e.g. opioids in pain disorders, serotonin in depression).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086748     DOI: 10.1016/s0166-2236(02)02181-1

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  34 in total

Review 1.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 2.  Applying evidence to support ethical decisions: is the placebo really powerless?.

Authors:  Franz Porzsolt; Nicole Schlotz-Gorton; Nikola Biller-Andorno; Anke Thim; Karin Meissner; Irmgard Roeckl-Wiedmann; Barbara Herzberger; Renatus Ziegler; Wilhelm Gaus; Ernst Pöppe
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

Review 3.  The biochemical bases of the placebo effect.

Authors:  Raúl de la Fuente-Fernández; A Jon Stoessl
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

Review 4.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

5.  Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Jacqueline L Johnson; Peter J Schmidt; David R Rubinow
Journal:  Depress Anxiety       Date:  2017-07-17       Impact factor: 6.505

6.  Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation.

Authors:  Antonio P Strafella; Ji Hyun Ko; Oury Monchi
Journal:  Neuroimage       Date:  2006-03-20       Impact factor: 6.556

Review 7.  Therapies for Restless Legs in Parkinson's Disease.

Authors:  Valérie Cochen De Cock
Journal:  Curr Treat Options Neurol       Date:  2019-11-09       Impact factor: 3.598

8.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

9.  Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.

Authors:  Alberto J Espay; Matthew M Norris; James C Eliassen; Alok Dwivedi; Matthew S Smith; Christi Banks; Jane B Allendorfer; Anthony E Lang; David E Fleck; Michael J Linke; Jerzy P Szaflarski
Journal:  Neurology       Date:  2015-01-28       Impact factor: 9.910

10.  Genetic biomarkers of placebo response: what could it mean for future trial design?

Authors:  Kathryn T Hall; Ted J Kaptchuk
Journal:  Clin Investig (Lond)       Date:  2013-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.